News
Midwest Allergy Sinus Asthma, SCNeffy: A Nasal Spray Alternative to EpiPen approved by FDA in the U.S.
FDA approved Epinephrine nasal spray (neffy) for emergency treatment of allergic reaction type 1 in August in adults and pediatric patients who weigh at least 30 kg (or around 66 lbs). Neffy provides an option to treat anaphylaxis that does not involve injection,...
What is D.R.E.S.S? (Drug Reaction with Eosinophilia and Systemic Symptoms) [with Visual Handout]
Symptoms include fever, rash, facial swelling, enlarged lymph nodes and kidney or liver injury. Many drugs could cause D.R.E.S.S., but the most common drugs involved are specific types of antibiotics…
Non-steriodal cream treatment option approved by FDA for Atopic Dermatitis (Roflumilast cream)
The FDA approved Zoryve cream (0.15%) for mild to moderate atopic dermatitis this year for adults and children aged above 6 years old. Roflumilast cream (marketed under the name Zoryve) is a non-steroidal topical cream that is applied once daily to affected areas of...
FDA Greenlights Pemgarda for High-Risk COVID-19 Prevention
This is particularly important for the immunocompromised population, who are at greater risk of severe illness and have a diminished response to vaccines.
FDA approved chronic sinusitis medication without nasal polyps
US FDA approved of XHANCE as the first and only medication for adults with chronic rhinosinusitis without nasal polyps. It is a fluticasone propionate nasal spray which uses the Exhalation Delivery System to enable topical steroid to the inflamed areas and is proven effective.
CIIC Patient Scholarship Call 2024
CIIC Annual Patient Scholarship: Empowering PIDD and Rare Disease Patients The CIIC (Coalition of Immunology and Allergy Clinics) is proud to announce the continuation of its Annual Patient Scholarship program, initiated in 2021. This unique scholarship is...
Listen: Dr. Siri explains Hereditary Angioedema (HAE) in podcast “Swell Conversations”
Dr. Dareen Siri was invited to share her experience in “Simplifying the Science, the Root Cause of HAE”, which is part one of the HAE podcast series where in each episode is a conversation with another HAE expert trying to dig into some of the nuances of hereditary...
MASA+R Team Tested the First Patient in a Phase-3 “Viaskin” Clinical Trial in Peanut-Allergic Children
The first patient in the VITESSE clinical trial was screened in Normal, Illinois, by the research team led by Principal Investigator Dr. Dareen Siri MD FAAAAI, FACAAI. Dr. Siri is among the Principle Investigators leading clinical trials across United States, Canada,...
Status of Vitamin D in Children with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS)
MASA news: Gabriel Delgado, senior at Illinois Math and Science Academy Class of 2022, who took part in the IMSA business mentorship program hosted by Dr Siri and MASA/SWIA, was chosen for an oral poster presentation to share his research project at the 2022 American...